This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | Next revisionBoth sides next revision | ||
home:diseases:cancer [04.26.2019] – [Are There Concerns About V.D Supplement ?] sallieq | home:diseases:cancer [05.16.2019] – [Recent research] sallieq | ||
---|---|---|---|
Line 380: | Line 380: | ||
Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer. (({{pubmed> | Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer. (({{pubmed> | ||
+ | |||
+ | This compound has antiproliferative and antimigratory effects in squamous cell carcinoma, glioblastoma, | ||
Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as anticancer drugs in future. | Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as anticancer drugs in future. |